2T

Asensus Surgical IncFRA Asensus Stock Report

Last reporting period 31 Mar, 2024

Updated —

Last price

Market cap $B

0.095

Micro

Exchange

XFRA - Deutsche Boerse AG

2TX.F Stock Analysis

2T

Uncovered

Asensus Surgical Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

9/100

Low score

Market cap $B

0.095

Dividend yield

Shares outstanding

239.28 B

Asensus Surgical, Inc. is a medical device company, which digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. The company is headquartered in Durham, North Carolina and currently employs 183 full-time employees. The firm is focused on the market development and commercialization of the Senhance Surgical System, which digitizes laparoscopic minimally invasive surgery (MIS). The Senhance System is a digital and multi-port laparoscopic platform designed to maintain laparoscopic MIS standards while providing digital benefits, such as haptic feedback, robotic precision, comfortable ergonomics, advanced instrumentation, including three-millimeter (mm) micro laparoscopic instruments, five mm articulating instruments, eye-sensing camera control and fully reusable standard instruments to patients around the world. Its Senhance System is used in Europe for adult and pediatric laparoscopic abdominal and pelvic surgery, as well as limited thoracic operations. The company is also available in the United States, Japan, Taiwan and Russia.

View Section: Eyestock Rating